Interleukin 16 (IL-16; previously known as lymphocyte chemoattractant factor) is a chemokine expressed by a variety of different cells such as CD8+ T cells, macrophages, and endothelial cells. 8,9 The IL-16 protein is produced in a pro-IL-16 form, which is later cleaved by caspase-3.10,11 CD4+ T cells have been found in large numbers in the intima, at the site of inflammation and plaque formation. 12 It is known that IL-16 acts as a chemoattractant on CD4+ T cells and is thought to inhibit the T-cell receptor, making the cells incapable of proliferation after antigen stimulation.13 IL-16 is a pleiotropic cytokine with proinflammatory, Th1-promoting Background and Purpose-Interleukin-16 (IL-16) functions as a regulator of T-cell growth and acts as an inducer of cell migration. The aim of this study was to determine whether IL-16 measured in human carotid plaques was associated with symptoms (eg, stroke, transient ischemic attack, or amaurosis fugax), markers of plaque stability, and postoperative cardiovascular events. Methods-Plaques obtained from patients who had ≥1 cerebrovascular ischemic events within 1 month before endarterectomy (n=111) were compared with plaques from patients without symptoms (n=95). Neutral lipids, smooth muscle cell, and macrophage contents were evaluated histologically, and collagen, elastin, and caspase-3 activity were measured biochemically. IL-16, matrix metalloproteinases, and tissue inhibitors of metalloproteinases were measured in plaque homogenates using a multiplex immunoassay. IL-16, CD3, CD4, and FoxP3 mRNA expressions in carotid plaques were analyzed with quantitative real-time polymerase chain reaction. Results-Carotid plaques from asymptomatic patients had higher levels of IL-16 mRNA. High plaque IL-16 protein levels (above median) were associated with reduced incidence of postoperative cardiovascular events during a mean follow-up of 21 months (hazard ratio, 0.47; 95% confidence interval, 0.